Evidence map›Paper›PMID 42180128›Full record

ReviewFrontiers in oncology2026

Breast cancer chemotherapy in transition: predictive markers, resistance mechanisms, and new treatment approaches.

Rakesh Sharma, Leelabati Toppo, Prakasini Satapathy, Rekha Arcot, Chandana Maji, Sorabh Lakhanpal, Sanjay Kumar, Do-Youn Lee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rakesh SharmaDepartment of Biochemistry, Graphic Era Deemed University, Dehradun, India.
Leelabati ToppoDepartment of General Medicine, Malla Reddy Medical College for Women, Telangana, India.
Prakasini SatapathySchool of Medical Sciences and Research, Sharda University, Greater Noida, India.
Rekha ArcotDepartment of surgery, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Maharashtra, India.
Chandana MajiNoida Institute of Engineering & Technology (Pharmacy Institute), Greater Noida, India.
Sorabh LakhanpalSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Sanjay KumarCentre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Do-Youn LeeCollege of General Education, Kookmin University, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains the most frequently diagnosed malignancy among women worldwide and continues to be a major cause of cancer-related mortality despite substantial therapeutic progress. Chemotherapy remains a central component of treatment, especially in high-risk early breast cancer, triple-negative breast cancer (TNBC), HER2-positive disease, and selected hormone receptor-positive tumors. Over the last two decades, the role of chemotherapy in breast cancer has evolved from a largely uniform cytotoxic approach to a more nuanced strategy guided by tumor biology, response dynamics, and residual disease burden. Neoadjuvant chemotherapy has become particularly important, not only for tumor downstaging but also for providing an

Indexed as

breast cancerchemotherapydrug resistanceneoadjuvant therapypredictive biomarkerstherapeutic strategies

Identifiers

PMID42180128
PMCPMC13193801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.